FMP
Annovis Bio, Inc.
ANVS
NYSE
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
5.01 USD
0.55 (10.98%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Mark K. White
sector
Healthcare
industry
Biotechnology
website
https://www.annovisbio.comexchange
NYSE
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
CIK
0001477845
ISIN
US03615A1088
CUSIP
03615A108
Address
1055 Westlakes Drive
Phone
610 727 3913
Country
US
Employee
6
IPO Date
Jan 29, 2020
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ANVS Financial Summary
CIK
0001477845
Exchange
NYSE
Industry
Biotechnology
Sector
Healthcare
CUSIP
03615A108
ISIN
US03615A1088
Country
US
Price
5.01
Beta
1.7
Volume Avg.
284.26k
Market Cap
69.12M
Shares
-
52-Week
4.21-22.49
DCF
0.64
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.19
P/B
-
Website
https://www.annovisbio.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ANVS News
It looks like there's no news available.
